Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

Advances in the kokumi 'taste sensation' for food

Six on the shelf: functional drink, protein-powered snack and more

Dr Mark Krstic is stepping down as MD of AWRI

Turning apple by-products into food packaging of the future

ARBSQLD returns to Brisbane in 2027

The Fair Work Ombudsman finds 13 out of 22 aged care providers non-compliant

"Bed block is accelerating and is far beyond sustainable," NSW Minister for Health says

Eureka Prize-winning discovery affects one in four women worldwide

Medicare Mental Health Check In — helping clinicians close the gap

Health professionals FAQ for Medicare Mental Health Check In

Guide to assessing low‍-‍emissions thermal energy storage released

WA invests in local wind generator repair and refurbishment

UTS pilot project to mitigate methane emissions

Partners to bring Aussie batteries to global defence and security market

ARENA invests $105.6 million in latest solar innovation

Lonza bone marrow and cord blood mononuclear cells

TRC stable isotope labelled (SIL) compounds

Cayman Chemical Prostaglandin Screening Library I (96-Well)

Bioss Multiplex Fluorescent IHC Staining Kit

Content from other channels on our network